Who Paid My Doc
Amanda Shepard Hayes
Pediatric Dermatology Grand Rapids, MI Medical Doctor
NPI 1922458736 CMS profile 1626330
35 Michigan St Ne Ste 5201, Grand Rapids, MI 49503
General payments
$49
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amanda Shepard Hayes of Grand Rapids, MI is reported in the CMS Open Payments database as having received $49 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 9th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $49 | 2 |
Beside peers
- Amanda Shepard Hayes
- Pediatric Dermatology median
- Middle half of Pediatric Dermatology
- National median
In program year 2025, general payments to Amanda Shepard Hayes were reported at $49. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.
Show as a table
| Year | Amanda Shepard Hayes | Pediatric Dermatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $280 | $89–$1,853 | $163 |
| 2020 | $0 | $263 | $71–$2,376 | $114 |
| 2021 | $0 | $227 | $69–$1,800 | $132 |
| 2022 | $0 | $289 | $69–$1,516 | $149 |
| 2023 | $0 | $537 | $114–$3,255 | $160 |
| 2024 | $0 | $437 | $114–$2,693 | $164 |
| 2025 | $49 | $302 | $110–$2,128 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 5 drugsPart D claims
117
Drug cost
$3,431
Branded share of claims
11.1%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | Brand | 13 | $1,212 | |
| Clobetasol Propionate | Generic | 28 | $728 | |
| Hydroxychloroquine Sulfate | Generic | 15 | $609 | |
| Triamcinolone Acetonide | Generic | 43 | $536 | |
| Ketoconazole | Generic | 18 | $345 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Dermatology in Michigan
Tor Shwayder
Pediatric Dermatology · Detroit, MI
Rachel Laarman
Pediatric Dermatology · Rockford, MI
Marla Jahnke
Pediatric Dermatology · Detroit, MI
Katherine Foster
Pediatric Dermatology · Grand Rapids, MI
Allison Zarbo
Pediatric Dermatology · Detroit, MI
Jennifer Mancuso
Pediatric Dermatology · Ann Arbor, MI
Related records
Pediatric Dermatology in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Dermatology
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.